# Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

> **NCT04837859** · PHASE2 · RECRUITING · sponsor: **University of Cologne** · enrollment: 120 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT04837859
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-05
- **Final completion:** 2028-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04837859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04837859, "Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04837859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*